tradingkey.logo
tradingkey.logo
Pesquisar

ADMA Biologics Inc

ADMA
Adicionar à lista de desejos
8.610USD
+0.240+2.87%
Fechamento 07/01, 16:00ETCotações atrasadas em 15 min
2.00BValor de mercado
12.38P/L TTM

Mais detalhes de ADMA Biologics Inc Empresa

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

Informações de ADMA Biologics Inc

Código da empresaADMA
Nome da EmpresaADMA Biologics Inc
Data de listagemOct 17, 2013
CEOGrossman (Adam S)
Número de funcionários677
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 17
Endereço465 State Route 17
CidadeRAMSEY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal07446
Telefone12014785552
Sitehttps://www.admabiologics.com/
Código da empresaADMA
Data de listagemOct 17, 2013
CEOGrossman (Adam S)

Executivos da empresa ADMA Biologics Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Adam S. Grossman
Mr. Adam S. Grossman
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.94M
-33.49%
Dr. Jerrold B. Grossman
Dr. Jerrold B. Grossman
Vice Chairman of the Board, Co-Founder
Vice Chairman of the Board, Co-Founder
602.30K
+5.21%
Mr. Lawrence P. Guiheen
Mr. Lawrence P. Guiheen
Independent Director
Independent Director
175.82K
+10.98%
Mr. Steven A. (Steve) Elms
Mr. Steven A. (Steve) Elms
Independent Chairman of the Board
Independent Chairman of the Board
87.33K
-12.24%
Mr. Eduardo Rene Salas
Mr. Eduardo Rene Salas
Independent Director
Independent Director
10.89K
-98.17%
Mr. Brad L. Tade
Mr. Brad L. Tade
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
2.03K
-12280.23%
Dr. Young T. Kwon, Ph.D.
Dr. Young T. Kwon, Ph.D.
Independent Director
Independent Director
--
--
Ms. Alison C. Finger
Ms. Alison C. Finger
Independent Director
Independent Director
--
--
Ms. Kaitlin Kestenberg
Ms. Kaitlin Kestenberg
Chief Operating Officer, Senior Vice President - Compliance
Chief Operating Officer, Senior Vice President - Compliance
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Adam S. Grossman
Mr. Adam S. Grossman
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.94M
-33.49%
Dr. Jerrold B. Grossman
Dr. Jerrold B. Grossman
Vice Chairman of the Board, Co-Founder
Vice Chairman of the Board, Co-Founder
602.30K
+5.21%
Mr. Lawrence P. Guiheen
Mr. Lawrence P. Guiheen
Independent Director
Independent Director
175.82K
+10.98%
Mr. Steven A. (Steve) Elms
Mr. Steven A. (Steve) Elms
Independent Chairman of the Board
Independent Chairman of the Board
87.33K
-12.24%
Mr. Eduardo Rene Salas
Mr. Eduardo Rene Salas
Independent Director
Independent Director
10.89K
-98.17%
Mr. Brad L. Tade
Mr. Brad L. Tade
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
2.03K
-12280.23%

Perguntas frequentes

Quem são os cinco principais acionistas de ADMA Biologics Inc?

Os cinco principais acionistas de ADMA Biologics Inc são: Mr. Adam S. Grossman

Quantas instituições possuem ações da ADMA Biologics Inc (ADMA)?

Em 2026Q1, 784 instituições possuíam ações da ADMA Biologics Inc, com valor de mercado aproximado de 218.01M, representando 94.06% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -33855143.00.